cms.bioaccessla.com

Blog

  • Investigational Device Import Is the LATAM FIH Bottleneck Nobody Puts on the Gantt

    The quietest way to miss first-patient-in in Latin America is to treat import as a shipping task. Ethics stamped the protocol. The regulator stamped the study. The implanting physician blocked a room. The crate is still in customs because nobody owned the investigational import as its own permit.

    Clinical-trial authorization and investigational import are different legal objects. One lets you treat patients under a protocol. The other lets a specific lot, in a specific packaging configuration, cross a border for that protocol. Mixing them with a future commercial registro is how devices sit on a tarmac while the site calendar dies.

    What you are actually waiting on

    After the CEI / IRB letter, the bottleneck is usually not “more patients.” It is:

    1. A named importer of record (IOR) who is allowed to receive investigational devices in that country.
    2. A permit or license that cites the protocol, the device identity, the quantity, and the site — not a commercial sanitary registration number you do not have yet.
    3. A packing list, invoice, and airway bill that match that permit. “We’ll fix the HS code at the airport” is not a strategy.
    4. A chain of custody into the investigational pharmacy or device accountability log. If the box lands at a distributor who is your future commercial holder, you have started the wrong file.

    The commercial holder conversation — titular versus distributor, who should own the future registro — is a different article. See Titular de registro LATAM vs distribuidor. Do not use the trial IOR as the future registration holder “to save a contract.” Cheap in month one. Expensive when you want a second importer or an inspection.

    Four import clocks — trial, not launch

    These are first-in-human clocks. They expire with the study. They do not become a commercial entry.

    INVIMA (Colombia)

    Colombia is often the fastest ethics-plus-regulator pair when the dossier is complete: CEI review in parallel with INVIMA, then an INVIMA-issued import permission tied to the authorized study. The import is not a side errand for the site. If the importer named on the permit is not the entity that will sign the warehouse, the crate waits. Plan the importer identity in the same week you lock the PI, not the week the airway bill is cut. INVIMA home: invima.gov.co.

    ANVISA (Brazil)

    Brazil’s device-trial pathway (DICD under RDC 837/2023 for the clinical file) still leaves you with a separate import license problem. Investigational entry runs through an import license (licença de importação) and the rules that govern investigational-product importation — sponsors still treat RDC 39 as the operational text they have to satisfy, not a footnote. Portuguese documents, a regularized Brazilian company, and a quantity that matches the protocol. Class I/II device FIH can be CEP-leaning on the clinical side and still fail in customs if the import file is a US commercial invoice. ANVISA: gov.br/anvisa.

    COFEPRIS (Mexico)

    Mexico is where teams confuse the two DIGIPRiS doors. Protocol authorization is not a Permiso Sanitario de Importación. You need both, and the import permission has to describe the investigational lots. A Mexican legal representative who is ready for a future registro is not automatically the consignee for a protocol-only shipment. If first-patient-in is on a surgical calendar, start the import permission when the CEI pack goes in, not when the surgeon asks where the device is. COFEPRIS: gob.mx/cofepris.

    ANMAT (Argentina)

    ANMAT’s 2026 trial-authorization conversation (including the 62-day framework sponsors are now planning against) still sits next to an import permission under the investigational-product rules — Disposición 4457 is the text operations teams keep on the wall. Tariff cuts on commercial medical devices do not rewrite an investigational import. HELENA is the commercial desk; it will not undock your FIH crate. ANMAT: argentina.gob.ar/anmat.

    Documents that actually move the crate

    • Protocol identifier and ethics / regulator authorization numbers on the commercial invoice and packing list.
    • Device identity that matches the investigator’s brochure: model, lot/serial, sterile barrier, software version if it is part of the investigational article.
    • Quantity that a reviewer can reconcile to the protocol’s sample size plus spares — not a “launch inventory” number.
    • Consignee = trial IOR. Notify party = site or CRO. Not your future distributor “so they can learn the product.”
    • Temperature, dangerous-goods, and battery declarations written once, used everywhere. Rewriting them at the handling agent is how you miss the implant slot.

    Calendar, not folklore

    I do not publish a fake “import is always 10 days” number. Agency queues and customs holds are outside any CRO’s control. What is inside your control is sequencing:

    1. Week 0 with site selection: name the trial IOR. If you cannot name the importer, you do not have a country.
    2. Same week the CEI pack is submitted: draft the import dossier (invoice template, packing list, authorization citations). Do not wait for the approval letter to invent the paperwork.
    3. On approval: file import immediately. First-patient-in is a hospital calendar. Import is a permit calendar. They only meet if you started both.
    4. After last patient: close investigational inventory. Do not “leave the leftover lots with the site for commercial use.” That is a new sanitary-registration and a new commercial import — see the post-FIH sequence.

    OUS FIH data can support an IDE or a device marketing submission when the investigation meets 21 CFR 812.28 GCP (IEC review, consent, traceable conduct). Eligibility of foreign clinical data is not FDA clearance. A missing import trail is how you lose device accountability, which is how you lose the GCP story.

    Commercial IOR economics are a different contract. bioaccess®’s public LATAM Launch Subscription (USD 7,500 per year per country for the first device family; higher for Mexico Class III / energy and Brazil Class III/IV) is a sanitary-holder architecture, listed on the pricing page. Investigational import is billed and permitted as study conduct. Do not budget them as the same line. Market-access hub: bioaccess® market access.

    Three import mistakes I still see after the ethics letter

    1. Cutting the airway bill to the PI “because he is the investigator.” Unless that person is the licensed importer, customs does not care about the protocol.
    2. Using a commercial sanitary registration number from a predicate or a cousin SKU. The investigational article is not that product.
    3. Scheduling first implant on the ethics-approval date plus two weeks, with no import owner. That is a hope, not a Gantt.

    This week: one page with four columns — Colombia, Brazil, Mexico, Argentina (or the subset you will actually open) — and four rows: IOR legal name, import-permit type, documents already in Spanish/Portuguese, and the first date a device can physically sit in the site’s accountability log. If quality, regulatory, and the person who signs freight cannot point to the same consignee, you are hoping, not importing.

    Disclosure: I am CEO of bioaccess®, a first-in-human / early-feasibility medical-device CRO with US regulatory anchoring and Latin American execution. The import sequence above is how I tell sponsors to put the crate on the calendar; it is not a guarantee of any permit, and it is not a CRO hard-sell. Self-reported ~40% faster / ~30% lower per-patient cost figures used elsewhere on bioaccessla.com are experience since 2010, not a formal study, and they assume the import workstream was actually staffed.

  • FDA QMSR Is Live: What LATAM Registration Holders Must Actually Show

    FDA’s Quality Management System Regulation did not stay in Silver Spring. The rule is US law. The calendar it now collides with is INVIMA, ANVISA, COFEPRIS, and ANMAT — because your Latin American registration holder still has to produce a quality system, not a slide that says “we are ISO-aligned now.”

    On 2 February 2024 FDA published the final rule amending 21 CFR Part 820 (89 FR 7496). The effective date was 2 February 2026. The revised part is titled the Quality Management System Regulation (QMSR). FDA’s own description is not subtle: the QMSR incorporates ISO 13485:2016 by reference and keeps additional FDA requirements so that incorporation does not fight the rest of the FD&C Act. Primary text: Federal Register, 89 FR 7496.

    Six months after the effective date, the bottleneck I still see is not “did we buy an ISO certificate.” It is whether the person who will hold your sanitary registration in Brazil, Mexico, Colombia, or Argentina can actually retrieve design controls, supplier control, labeling, and a complaint / tecnovigilancia loop that match the configuration you intend to sell.

    What QMSR is — and what it is not

    QMSR is current good manufacturing practice for devices under US jurisdiction, rewritten onto an ISO 13485 architecture. It is not:

    • A substitute for ISO 13485 certification. FDA incorporated the standard by reference; it did not outsource inspections to a registrar. A certificate on the wall is evidence of a third-party audit. It is not evidence that FDA, or INVIMA, or ANVISA, has accepted your file.
    • A Brazilian, Mexican, Colombian, or Argentine quality-system approval. ANVISA still runs its own GMP (BGMP) clock for higher-risk equipment. COFEPRIS still wants a licensed Mexican establishment. INVIMA still wants a complete sanitary-registration file and a competent local importer (CCAA) where the rules require one. ANMAT still wants a locally enabled manufacturer/importer on HELENA.
    • A clinical-trial authorization. QMSR does not move a first-in-human ethics letter, an investigational import permit, or an IDE. Mixing those clocks is how teams lose a quarter.

    The Federal Register text is explicit that FDA retained additional requirements so ISO 13485 would not create inconsistencies with other FDA rules — including control of records and labeling/packaging expectations that sit on top of the ISO clauses. If your LATAM holder can produce an ISO 13485 certificate and cannot produce the labeled, language-correct IFU that matches the registered models, you do not have a QMS. You have stationery.

    Why a LATAM holder feels QMSR as a calendar event

    Sanitary registration is held by a local legal person in most of the region. Colombia is the structural exception: a foreign manufacturer can hold the INVIMA registro with a local legal representative, but the importer still has to be a licensed actor. Everywhere else, the holder is the face of the file.

    That holder is who an inspector, an agency query, or a customs officer will ask for:

    1. The locked configuration — models, accessories, software version, sterile barrier, intended use.
    2. The design- and production-control evidence that QMSR now describes in ISO 13485 language (risk throughout the system, not a separate “risk binder”).
    3. Spanish or Portuguese labeling that matches that configuration. English source files that are still in draft are a lock problem, not a translation problem.
    4. A post-market / tecnovigilancia owner. ISO 13485 complaint handling is not automatically INVIMA tecnovigilancia, ANVISA notificações, COFEPRIS farmacovigilancia/tecnovigilancia, or ANMAT’s local reporting clock.

    If those four items live only at the US legal manufacturer and the holder is a mailbox, QMSR did not “harmonize” anything for you. It made the mailbox more obvious.

    Four country clocks — registration QMS, not trial QMS

    These are market-access clocks. They are not the investigational QMS you used to import a protocol-only lot.

    ANVISA (Brazil) — BGMP is still the Brazil clock

    ANVISA’s device regime under RDC 751/2022 is notification (Classes I/II) versus registro (Classes III/IV). For Classes III and IV, the manufacturing unit’s Brazilian GMP certificate is often the real wait — not whether FDA now speaks ISO 13485. Start the BGMP petition when you lock the manufacturing site, not when you lock the US QMSR gap assessment. The Brazil Registration Holder (detentor) is usually a different company from the trial importer of record. Align them before you translate the technical file. See ANVISA.

    COFEPRIS (Mexico) — the titular is the licensed establishment

    Mexico’s registro sanitario is promoted by a Mexican titular. DIGIPRiS is a filing desk, not a quality system. Equivalence / abbreviated routes that lean on FDA, EU, Japan, or Health Canada can compress review when you actually have a reference-authority approval to rely on. They do not replace a holder, Spanish labeling (NOM-137 is the usual label conversation), or an establishment that can be inspected. QMSR may make your US file easier to map. It does not make COFEPRIS a US inspectorate. See COFEPRIS.

    INVIMA (Colombia) — class still decides the queue

    INVIMA’s sanitary registration under Decreto 4725 de 2005 is the document that authorizes production, import, and commercialization — not the trial permit you already ran. Risk I/IIA files can move on a complete administrative/technical pack. Risk IIB/III still go through prior evaluation. FIH tables help a high-risk file. They do not skip the unique INVIMA form, Spanish labeling, or the licensed importer. A QMSR-aligned design-history file that still lists “TBD distributor” will stall the same way a 2015 QSR file did. See INVIMA and the practitioner checklist at INVIMA medical device registration checklist.

    ANMAT (Argentina) — HELENA is the commercial desk

    ANMAT’s commercial device filings run through Sistema HELENA. HELENA is not your ethics committee and it is not FDA. After you lock configuration you need a locally enabled manufacturer/importer, a class-correct expediente, and Spanish files. Company habilitation started after the CSR is how Argentina “looks slow.” QMSR vocabulary in the US file does not create an Argentine digital signature. See ANMAT and ANMAT medical device registration checklist.

    The three QMSR mistakes that waste LATAM months

    1. Treating ISO 13485 certification as the LATAM dossier. Chile’s ISP has long recognized ISO 13485 in its own way. That is Chile. It is not a regional passport. Brazil BGMP, Mexican establishment licensing, and Argentine habilitation remain national acts.
    2. Leaving labeling and UDI as a “US workstream.” QMSR kept FDA’s hand on labeling and packaging. LATAM agencies will still refuse a file whose IFU, label, and registered models do not match. One source IFU, four translations — not four marketing decks.
    3. Appointing a holder who cannot sit an inspection. If the only person who can retrieve CAPA, supplier files, and complaint records is in California, your “local holder” is a courier. That was a bad idea under the old QSR. It is a worse idea now that the US rule and ISO 13485 use the same nouns.

    A week-zero sequence that does not fight itself

    1. Write a one-page QMS map: US legal manufacturer, contract manufacturers, and each LATAM holder. Three rows: who owns design lock, who owns production/release, who owns complaints/tecnovigilancia.
    2. Freeze the commercial identity you are willing to put on a Spanish/Portuguese label. If the next three design changes will rewrite the IFU, you are still in design, not in registration.
    3. Start the national clocks that do not care about QMSR: ANVISA BGMP petition, Mexican establishment/holder appointment, INVIMA importer identity, ANMAT HELENA habilitation.
    4. Do not wait for an FDA inspection under the new program to “prove” the system to Latin America. Local agencies will not sit that inspection for you.

    Holder economics are public and separate from government fees. bioaccess®’s LATAM Launch Subscription is USD 7,500 per year per country for the first device family (Mexico Class III / energy and Brazil Class III/IV are higher; extras and pass-throughs are listed on the pricing page). That number buys an in-country holder architecture — titular / detentor / representante, translations, agency liaison, post-approval modifications, tecnovigilancia as holder. It does not buy ANVISA BGMP, INMETRO, or a customs entry. See the hub: bioaccess® market access.

    For the post-FIH version of this split — trial IOR versus commercial holder — I already walked the evidence room in After First Patients: How to Sequence FDA/IDE Data and LATAM Registration. This piece is the QMS half of that calendar.

    Disclosure: I am CEO of bioaccess®, a first-in-human / early-feasibility medical-device CRO and LATAM launch / in-country-holder group. The sequencing above is how I tell sponsors to think about the QMSR–LATAM collision; it is not a claim that FDA, INVIMA, ANVISA, COFEPRIS, or ANMAT has accepted any specific file, and it is not a pitch for a particular vendor to hold your registration. ~40% faster / ~30% lower per-patient cost figures used elsewhere on bioaccessla.com are self-reported experience since 2010, not a formal study — they are not QMSR outcomes.

  • RC&C Consultores ARCSA Holding vs bioaccess® LATAM Launch Subscription

    RC&C Consultores is the homegrown Ecuador shop that publishes “Holding de Registros” in so many words. The homepage registrossanitariosrcc.com (retrieved 23 August 2026) says they act as legal titulares before ARCSA so a foreign company can work with multiple distributors and not be tied to one. They also publish a BPADT-certified warehouse. That is a one-country holding + storage product. bioaccess® is the multi-country holder subscription that names ARCSA among 19 markets.

    What RC&C publishes

    Public facts on the homepage:

    • More than 12 years obtaining sanitary registrations in Ecuador (their figure); they also cite experience with more than 1,400 registros sanitarios.
    • ARCSA registros and notificaciones for devices, food supplements, foods, cosmetics, hygiene products, and medicines.
    • Legal representation / holding / IP as a service tile.
    • Explicit holding paragraph: they offer Holding de Registros so the foreign company keeps total control; they act as legal titulares before ARCSA; multiple distributors without being tied to any one of them.
    • Bodega certificada BPADT (Buenas Prácticas de Almacenamiento, Distribución y Transporte) for devices and pharmaceuticals from receipt to delivery, under ARCSA rules.
    • Contact published on-site: +593 99 777 3359 / +593 99 260 1838; asesoria@consultarcc.com. Named as RC&C Consultores, 2015 in the footer.

    ARCSA issues the sanitary registry certificate in the name of the holder, who is responsible for its use (Resolución ARCSA-DE-026-2016-YMIH, reformed by ARCSA-DE-2023-033-AKRG, as cited on the bioaccess® IOR page). Registration must be held by a local Ecuadorian company — a single holder. That is why hosting plus warehouse is the independent analogue, and why a distributor-as-titular is a single point of failure. Ecuador does not have a dedicated bioaccess® country microsite as of this writing; ARCSA is named on the market-access hub.

    RC&C vs bioaccess®

    Dimension RC&C Consultores bioaccess®
    Public product Holding de Registros + ARCSA dossiers + BPADT warehouse LATAM Launch Subscription; own in-country entities
    Multi-distributor pitch Yes — explicit on the homepage Yes — holder is not the distributor; registration is not leverage
    Product mix Devices plus foods, cosmetics, medicines, hygiene Already FDA-cleared or CE-marked medical devices
    Geography Ecuador / ARCSA 19 LATAM markets including ARCSA
    Bundle / bridge Country holding (no published all-in LATAM fee) Gov fees + certified translations included; Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    RC&C is a fair Ecuador holding shop when ARCSA is the only authority on the plan. bioaccess® is the operator when Ecuador is one market in a multi-country hold and the manufacturer wants the same transfer doctrine from Quito to Mexico City and São Paulo.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Titular de registro LATAM vs distribuidor: la licencia no debe ser el canal

    El titular del registro sanitario no debería ser el distribuidor. Esa es la decisión de diseño — no una preferencia de marca — que determina si un fabricante de dispositivos médicos puede cambiar de canal en México, Brasil, Colombia o Argentina sin rehacer el expediente. Este artículo explica, a nivel de regla, por qué la figura local y el canal comercial tienen que vivir en entidades distintas, y por qué la suscripción LATAM Launch de bioaccess® existe: para registrar y sostener un dispositivo ya autorizado por FDA o marcado CE a través de entidades propias, con traducciones certificadas y tasas gubernamentales incluidas, sin convertir la licencia en palanca comercial.

    Qué es el titular — y qué no es

    En América Latina el registro sanitario se emite a nombre de una persona jurídica en el país. Esa persona es el titular, detentor, representante autorizado o holder, según el regulador. Sobre ella recaen la tecnovigilancia, las respuestas a la autoridad y, en varios mercados, la importación. El distribuidor es otra función: vende, factura, da servicio. Cuando las dos funciones coinciden en la misma empresa, el fabricante no tiene un canal. Tiene un socio que también es dueño del activo regulatorio. Cambiarlo implica cesión de derechos, un nuevo registro, o ambos.

    Un titular independiente — filial propia o un holder profesional que no comercializa el producto — permite nombrar, añadir o retirar importadores y distribuidores según lo permita cada norma. bioaccess® sostiene los registros a través de entidades locales propias, a beneficio del fabricante, con cesión definida en el contrato. El registro no es palanca. Detalle país por país: Importador de registro en LATAM.

    Países con varios importadores sobre un mismo registro

    Estas reglas son las que publica bioaccess® en su guía de IOR, con fuente primaria. No son un ranking de consultoras.

    • México (COFEPRIS). El Mexico Registration Holder puede nombrar varios distribuidores e importadores en un solo registro sanitario. Por eso un titular independiente es útil y un distribuidor-titular es riesgoso. Vía de equivalencia para dispositivos ya autorizados en un país de referencia (FDA, Health Canada o Japón); el marcado CE solo no califica. Ver México — COFEPRIS.
    • Colombia (INVIMA). INVIMA contempla expresamente “un titular con varios importadores”. Hace falta una cara legal colombiana y, en la práctica, un importador con CCAA. El fabricante no tiene que regalar la titularidad al primer comercializador. Ver Colombia — INVIMA.
    • Brasil (ANVISA). RDC 751/2022 nombra un solo detentor de registro. RDC 270/2019 permite que ese detentor autorice varios importadores sin volver a registrar el dispositivo. El fabricante extranjero no puede ser el detentor. Un BRH que no es el importador exclusivo es el diseño correcto. Ver Brasil — ANVISA.
    • Perú (DIGEMID). El titular debe ser una droguería autorizada. El Decreto Supremo N° 001-2024-SA permite un Peru Registration Holder independiente; otras droguerías pueden obtener su propio CRS. De nuevo: titular ≠ catálogo comercial.
    • Chile (ISP), hoy. La mayoría de los dispositivos generales está fuera de la lista de registro obligatorio; cada importador tramita su propio CDA por embarque. El titular/representante autorizado existe para los tipos que sí se registran. La ley de Fármacos II, pendiente, va a endurecer el marco. Ver Chile — ISP.

    Países de un solo importador de registro

    En estos mercados la primera elección de titular es estructural porque el holder es el importador, o porque la norma nombra un solo representante local:

    • Argentina (ANMAT). El representante autorizado es titular e importador. Un AAR por registro. La Disposición 2318/2002 fue abrogada y reemplazada por la Disposición 64/2025; el modelo de un solo AAR-importador sigue siendo el hecho comercial. Cambiar de AAR suele significar volver a registrar. Ver Argentina — ANMAT.
    • Ecuador (ARCSA). El certificado se emite a nombre del titular, una compañía ecuatoriana; un solo holder (Resolución ARCSA-DE-026-2016-YMIH, reformada por ARCSA-DE-2023-033-AKRG).
    • El Salvador (SRS). Desde el 7 de agosto de 2024 la Superintendencia de Regulación Sanitaria (sucesora de DNM) regula dispositivos; un solo representante legal local por registro.
    • Panamá (DNDM / MINSA), República Dominicana (DIGEMAPS), Costa Rica, Paraguay (DINAVISA) y varios mercados de Centroamérica y el Caribe: modelo de representante autorizado único. Uruguay no está hoy en la cobertura publicada de bioaccess®.

    La lección no es “evite consultoras locales”. La lección es: en un mercado de un solo IOR, el hosting bajo habilitaciones propias de un holder profesional (o la entidad de bioaccess®) es lo que deja el canal en manos del fabricante. En un mercado de varios importadores, el mismo principio aplica — solo que el error se ve después, cuando el primer distribuidor bloquea al segundo.

    Qué incluye la suscripción de bioaccess® — y qué no inventamos

    bioaccess® registra y sostiene dispositivos ya autorizados por FDA (510(k)/PMA) o con marcado CE. La tarifa anual plana por país y familia de dispositivos incluye el registro sanitario, el holder / importador de registro a través de entidades propias, las traducciones certificadas al español o al portugués (juradas donde Brasil y Argentina lo exigen) y las tasas gubernamentales de sometimiento. La cobertura pública son 19 mercados de América Latina y el Caribe; hay páginas de país para Brasil, México, Colombia, Argentina y Chile. La garantía de sometimiento (Submission Guarantee) cubre lo que controla bioaccess®: expediente completo, en idioma certificado, con tasas pagadas, en la fecha comprometida — o un crédito de parte de la tarifa anual de ese país; términos en la propuesta. Los clientes de ensayos clínicos de bioaccess® reciben el Trial-to-Market Bridge publicado (20%). Las tarifas específicas están en revisión; hay que pedir cotización. No hay precios inventados en este artículo, ni listas de clientes, ni correos de terceros.

    Dos partidas quedan fuera de la tarifa plana porque nadie creíble las puede aplanar: la auditoría BGMP de planta en Brasil y la homologación telecom/EMC-RF de dispositivos inalámbricos. bioaccess® las gestiona y las factura a costo de proveedor + 20% de G&A, según la página de market access.

    bioaccess® no es el titular “de un solo país que también distribuye”. Es el holder multi-país que no es el distribuidor. Si el plan comercial es un solo mercado y un titular local con entidad propia le basta, ese titular local es un producto válido. Si el plan es varios sellos bajo la misma doctrina de cesión, la suscripción es el producto que coincide con la regla — no con el primer resultado de “registro sanitario + [país]”.

    Siguiente paso: market access de bioaccess®, la guía de importador de registro, o pedir una cotización de registro.

  • Farmaregistro El Salvador Titular vs bioaccess® LATAM Launch Subscription

    Farmaregistro S.A. de C.V. owns the domain that is the query: registrosanitarioelsalvador.com (retrieved 23 August 2026). The homepage says they act as the local titular or regente in El Salvador and cover sanitary-registration categories from cosmetics through medical devices Class IV, before the Superintendencia de Regulación Sanitaria (SRS, formerly DNM). That is a one-country titular / regente. This article names that offer, then explains when bioaccess® is the multi-country holder instead.

    What Farmaregistro publishes

    Public claims on the homepage:

    • 30+ years of experience (their figure).
    • Agile SRS management and dossier preparation to reduce preventions.
    • “Actuamos como tu titular o regente local en El Salvador.”
    • 360° regulatory support from cosmetics through device Class IV; also pharmaceutical, food/beverage, and veterinary product tiles.
    • Certification and liaison before SRS (ex-DNM).
    • Direct contact with the responsible professional, without intermediaries (their wording).
    • Clients in Central America, Mexico, the United States, France, India, Germany, Switzerland, Peru, “among others” — countries only; this page does not invent or copy named manufacturers.
    • San Salvador address published: Residencial Cima 1 #12-S, Calle 1.

    Since 7 August 2024 the Superintendencia de Regulación Sanitaria regulates medical devices as successor to DNM. El Salvador is a single local legal representative per registration. That is why “we will be your titular or regente” is the product that matches the statute — and why giving that role to an exclusive distributor is hard to unwind. Experience-based clocks on the bioaccess® market-access page put DNM/SRS device approvals on the order of ~30–60 days. There is no separate bioaccess® /market-access/el-salvador country page as of this writing; El Salvador is named on the hub and the IOR guide.

    Farmaregistro vs bioaccess®

    Dimension Farmaregistro S.A. de C.V. bioaccess®
    Public product Titular / regente local + SRS dossiers, many product classes LATAM Launch Subscription for already-cleared devices
    Device reach they publish Through Class IV Device registration as part of 19-market coverage; DNM/SRS named on the hub
    Geography El Salvador (domain owns the country query) 19 markets; own entities; holder not leverage
    Bundle Country RA / titular Gov fees + certified translations in one annual fee; Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    Farmaregistro is a fair SRS titular when El Salvador is the only label. bioaccess® is the operator when the same family must also be held in Mexico, Colombia, Brazil, or Argentina under one subscription, with the local face never becoming the commercial channel.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Pharma Consulting DIGEMID Holder vs bioaccess® LATAM Launch Subscription

    In Peru the sanitary-registration holder must be a DIGEMID-authorized pharmaceutical establishment (droguería) with a BPA warehouse and a químico farmacéutico as director técnico. “Independent holder” here means a droguería that will file and import without locking the manufacturer to its own commercial catalog. Pharma Consulting publishes that product at pharmaconsulting.pe/es/holder-de-registro-sanitario-en-peru/ (indexed holder URL as of 23 August 2026; the page is often Cloudflare-walled to automated fetch). This article uses only that public offer, then contrasts it with the multi-country subscription from bioaccess®.

    What Pharma Consulting publishes

    Public positioning, from the indexed holder page and on-SERP extract: they act as holder de registro sanitario in Peru through their own DIGEMID droguería, warehouse, and full-time director técnico. They file to DIGEMID. Site navigation lists devices, IVD, and prostheses among the product types they address. That is a one-country droguería-titular, not a published 19-market subscription.

    Peru’s current rule set (Decreto Supremo N° 001-2024-SA, as summarized on the bioaccess® IOR guide) permits an independent Peru Registration Holder; additional droguerías can obtain their own CRS. So the manufacturer can keep a neutral titular and still authorize more than one import path — if the first titular is not also the exclusive seller. Giving the droguería-titular role to the first commercial partner recreates the leverage problem under a different noun.

    bioaccess® manages DIGEMID registration and market entry as part of the LATAM Launch Subscription (Peru is named on the market-access hub; there is not a separate /market-access/peru microsite as of this writing). Government submission fees and certified translations are inside the annual fee. The holder is bioaccess®’s in-country structure, not the distributor.

    Pharma Consulting vs bioaccess®

    Dimension Pharma Consulting (Peru) bioaccess®
    Public product DIGEMID droguería titular + warehouse + DT LATAM Launch Subscription; own entities as holder/IOR
    Who must hold A licensed droguería (their establishment) Same legal constraint; bioaccess® supplies the in-country establishment
    Devices Devices / IVD / prostheses listed in nav Already FDA-cleared or CE-marked devices
    Geography Peru 19 LATAM markets including DIGEMID
    Bundle / bridge Country holder (no published all-in LATAM fee or FIH bridge) Gov fees + certified translations included; Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    Pharma Consulting is a fair Peru droguería titular. bioaccess® is the operator when Peru is one market next to COFEPRIS, ANVISA, INVIMA, or ANMAT, and the manufacturer wants one holder doctrine in all of them.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Budnik ANMAT Hosting vs bioaccess® LATAM Launch Subscription

    Argentina is a fused-holder market: the ANMAT Authorized Representative is typically the registration holder and the importer of record. Independent “hosting” shops that register under their own habilitaciones are the local analogue of a neutral titular. Budnik Regulatory Affairs publishes that product at bpregulatoryaffairs.com/hosting-productos-medicos (retrieved 23 August 2026). They are a fair one-country Argentina host. bioaccess® is the multi-country holder subscription that includes Argentina ANMAT among 19 markets.

    What Budnik publishes

    Hosting de Productos Médicos: they act as local representatives before ANMAT so national and international companies can register and import medical products in Argentina without their own habilitaciones. They say the model gives manufacturers a solid regulatory structure without requiring direct commercialization of the products — the manufacturer designs and manages its own local distribution network. They hold ANMAT habilitaciones that let them register under their titularidad different types and risk classes, assuming the corresponding sanitary responsibilities.

    Cycle they list: regulatory strategy and viability; preparation, filing, and follow-up of the sanitary registration, including requirements, plus lifecycle maintenance; local sanitary representation; import support (authorizations, inbound traceability, coordination with warehouses, logistics operators, and manufacturer-designated distributors); tecnovigilancia (adverse events, authority interaction, feedback to the manufacturer). They invite class-and-type scoping by email on that page. This article does not invent a product-class list they did not publish.

    Changing AAR in Argentina generally means re-registering. That is why the first holder choice is structural, not cosmetic. Foundational Disposición ANMAT N° 2318/2002 was abrogated and replaced by Disposición ANMAT N° 64/2025; the single-AAR-as-importer model remains the commercial fact sponsors plan around. Country page: Argentina — ANMAT.

    Budnik vs bioaccess®

    Dimension Budnik Regulatory Affairs bioaccess®
    Public product Hosting under own ANMAT habilitaciones + import support + tecnovigilancia LATAM Launch Subscription; own in-country entities
    Holder vs importer Fused, as ANMAT requires; they import without commercializing Same fusion in AR; holder is not leverage; defined transfer provisions
    Distribution Manufacturer keeps its own distributors (their page) Same doctrine across LATAM, not only Argentina
    Translations / gov fees Not published as an included multi-country annual bundle Certified/sworn translations + government submission fees included
    Geography Argentina 19 markets; ANMAT is one country page among five published cores
    Trial-to-market Not published Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    Budnik is a fair Argentina host when ANMAT is the only regulator on the plan. bioaccess® is the operator when the same family must also be held where holder and importer split (Mexico, Colombia, Brazil) and where they fuse (Argentina, El Salvador, Ecuador) — without hiring a new titular culture each time.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • DD9 Regulatorio INVIMA: Dossier Shop, Not a Clear Holder — vs bioaccess®

    Search “consultoría regulatoria INVIMA dispositivos médicos” and DD9 Regulatorio is often the Spanish result that owns the page. That is a dossier and representation shop. It is not a clear “we are your titular holder” product. Sponsors who confuse SERP strength with holder structure end up with an excellent expediente and a distributor still named on the registro. This article states what dd9regulatorio.com actually publishes (retrieved 23 August 2026), without repeating manufacturer names from their site, and then points to the holder subscription from bioaccess®.

    What DD9 publishes — and what it does not say

    DD9 Regulatorio is a firm specialized exclusively in sanitary regulation of medical devices and IVD before INVIMA. Public metrics on the homepage (theirs): 10+ years; 43 companies accompanied; zero sanctions / zero “negaciones de fondo” on managed filings; 100+ records managed simultaneously; 1,700+ trámites; 350+ sanitary registrations in the firm’s history. They describe a five-stage method: diagnóstico, estrategia, ejecución, monitoreo (they brand a Control Tower), actualización.

    Services they list: new registros, renewals, technical and legal modifications, responses to requerimientos, resolution corrections, CCAA certificates, manufacturer changes, importer changes, portfolio expansions, regulatory opinions, estándar semántico, tecnovigilancia, reactivovigilancia. Audiences: international manufacturers needing technical representation; importers and distributors with many records and different titulares; titulares needing maintenance; in-house RA teams; companies evaluating entry.

    Read that list again. They work for titulares, importers, and manufacturers. They change importers and manufacturers on existing records. They do not say “actuamos como titular holder.” That is the distinction versus Vexpro’s homepage sentence and versus bioaccess®’s own-entity hold. DD9 can be the right INVIMA dossier counsel. Someone still has to be the named titular and, usually, a CCAA importer. If that someone is the exclusive distributor, the SERP win did not solve the leverage problem.

    This page does not repeat client names that appear on DD9’s site. Company-published case anecdotes and success rates stay theirs.

    What INVIMA actually requires for a commercial launch

    Decreto 4725/2005: Class I and IIa receive registro sanitario automático (expedited issuance, verified post-hoc); Class IIb and III undergo full prior review on the order of ~90 business days. Foreign manufacturers need a Colombian legal face and typically a CCAA-licensed importer on the file. INVIMA allows one titular with several importers. Country page: Colombia INVIMA. IOR split: LATAM IOR.

    DD9 vs bioaccess®

    Dimension DD9 Regulatorio bioaccess®
    Public product INVIMA device/IVD dossier + representation Register + hold already-cleared devices through own entities
    Holder language Not a clear “we hold” shop In-country registration holder / IOR; registration not leverage
    SERP Owns Spanish INVIMA-device consultancy queries Market-access hub + country page + this intercept
    Geography Colombia 19 LATAM markets; gov fees + certified translations included
    Trial-to-market Not a published FIH CRO Colombia FIH CRO since 2010 + commercial registro as a separate live service; 20% Bridge

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    Keep DD9 in mind when the gap is an INVIMA expediente. Hire bioaccess® when the gap is who holds the license in Colombia and in the next four countries, and when that holder must not be the distributor.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Vexpro INVIMA Titular Holder vs bioaccess® LATAM Launch Subscription

    Vexpro Consultores (Bogotá) publishes a sentence most INVIMA consultancies do not: “Actuamos como titulares holder de sus registros sanitarios en Colombia.” That is a one-country holder product, not only a dossier shop. The homepage is vexproconsultores.com (public wording confirmed 23 August 2026). This article uses only that offer language. It does not copy manufacturer names from their site. Then it explains when the multi-country subscription from bioaccess® is the better holder.

    What Vexpro publishes (offer only)

    Public positioning: regulatory BPO for national and international companies; titularidad and legal representation before INVIMA; they act as titulares / holder of sanitary registrations in Colombia, including a cosmetics hosting role under Comunidad Andina NSO rules; a medical-device practice covering a range of device types (implants, electromechanical devices, consumables, software as a medical device) with sanitary-registration management and quality assurance. ConnectAmericas lists the legal name VEXPRO CONSULTORES LTDA and describes INVIMA registros plus quality-norm advisory across several product classes.

    INVIMA practice is messy in public commentary. Some shops say the foreign manufacturer can remain titular if a Colombian representante legal is named; others sell themselves as the titular holder. Vexpro sells the second sentence. Either way, an in-country entity — and often a CCAA-licensed importer — appears on the record. INVIMA explicitly contemplates “un titular con varios importadores” on one registro sanitario. That is why an independent holder (or an independent legal representative plus a licensed importer that is not the exclusive distributor) is the structure that keeps the channel replaceable. See Colombia — INVIMA.

    What Vexpro’s public holder line does not do: publish a 19-country own-entity subscription, include government fees and certified translations in one annual fee, or offer a trial-to-market bridge with a FIH CRO. They are a Colombia titular / BPO. Treat them as that.

    Vexpro vs bioaccess®

    Dimension Vexpro Consultores bioaccess®
    Public product “Titulares holder” + INVIMA BPO (devices among other classes) LATAM Launch Subscription for already-cleared devices
    Geography Colombia / INVIMA 19 LATAM markets; Bogotá regional office + local Colombian entity
    Importer split Not published as a multi-country IOR map INVIMA multi-importer rule documented on the IOR page; holder not leverage
    Bundle Country RA / holder (no published all-in LATAM fee) Gov fees + certified translations included
    Trial-to-market Not published Same operator can run the Colombia FIH and then hold the commercial registro; 20% Bridge

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    bioaccess® still runs clinical trials in Colombia and treats commercial registro sanitario as a separate live service — not a substitute for the trial, and not something the trial team has to re-learn with a second vendor. Vexpro is a fair INVIMA titular for a Colombia-only commercial file. bioaccess® is the operator when Colombia is one market in a multi-country hold, or when the manufacturer already used bioaccess® as the FIH CRO.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • DOMO Salute ANVISA Holder (Hospedagem + DDR) vs bioaccess® LATAM Launch Subscription

    DOMO Salute sells hospedagem de registros — Brazilian Registration Holder plus post-market work plus import authorizations (DDR) for named distributors. That is the Brazil product closest in shape to an independent holder who will also unlock the border. The public page is domosalute.com.br/pt/como-ajudamos/brazilian-registration-holder/ (retrieved 23 August 2026). This article names that offer fairly, then contrasts it with the multi-country LATAM Launch Subscription from bioaccess®.

    What DOMO Salute publishes

    They describe BRH as a fundamental step for international companies that want to regularize medical devices with ANVISA. As legal representative they assume responsibility for product regularization and ongoing compliance so manufacturers and local distributors can focus on commercial growth. As an independent BRH they advertise flexibility in choosing commercial partners and agility in managing records.

    Four blocks on the hospedagem page:

    • Local representation — technical and legal representative in Brazil; ANVISA regularizations.
    • Post-market — complaints, adverse-event notifications, corrective actions.
    • Renewals and regulatory updates — renewals, regularization updates, legislation monitoring, real-time alerts.
    • Import authorizations and compliance — they issue import authorizations (DDR) for designated distributors and qualify those partners.

    Related “Como Ajudamos” tiles: medical-device regularization including SaMD and IVD; hospedagem (they assume titularidade and sit between the international manufacturer and ANVISA); INMETRO & ANATEL certification support; BPF (good manufacturing practice) certification documentation for ANVISA.

    They do not publish a 19-country holder subscription or government fees plus certified translations inside one annual LATAM fee. They are a Brazil hospedagem + DDR shop. That is a strong one-country product — especially versus a BRH that refuses to touch import.

    Why DDR matters in Brazil

    ANVISA names a single detentor de registro. That detentor can authorize multiple importadores without re-registering the device. Import letters / DDR are how a neutral holder lets several distributors land product without becoming the exclusive commercial channel. A manufacturer that gives the BRH role to Distributor A has to unwind that appointment to add Distributor B. A manufacturer that keeps an independent BRH (DOMO’s model, or bioaccess®’s Brazilian entity) adds and drops importadores on paper. Country page: Brazil ANVISA.

    DOMO Salute vs bioaccess®

    Dimension DOMO Salute bioaccess®
    Public product Independent BRH / hospedagem + DDR + post-market LATAM Launch Subscription; own in-country entities
    Import DDR for designated distributors Holder/IOR through own Brazilian entity; multiple importers allowed under ANVISA rules
    Device types they name Devices, SaMD, IVD; INMETRO/ANATEL; BPF Already FDA-cleared or CE-marked devices; INMETRO/ANATEL/BGMP managed as carved-out third-party items on the public price page
    Geography Brazil 19 LATAM markets; certified translations + gov submission fees included
    Trial-to-market Not a published FIH CRO bridge Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    DOMO is a fair Brazil titular with import letters. bioaccess® is the operator when the same family must also be held in Mexico, Colombia, Argentina, Chile, or the rest of the published coverage — under one annual-fee shape, with the holder not used as leverage.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.